News | December 24, 2013

Q.Clear Delivers PET Quantitation, Image Quality

nuclear molecular imaging ge q.clear rsna 2013 pet systems q.suite
December 24, 2013 — GE Healthcare showcased at the Radiological Society of North America Annual Meeting (RSNA 2013) a work-in-progress product for positron emission tomography (PET) that quickly and confidently evaluates a patient’s response to cancer treatment. The Q.Clear tool provides up to two times improvement in both PET quantitative accuracy (SUVmean) and image quality (signal-to-noise ratio). Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare’s new 510(k)-pending Q.Clear technology on shows the advantage of full convergence PET imaging without compromise between quantitation and image quality. 
 
“We know that cancer patients don’t always respond to their initial course of treatment,” said Steve Gray, president and CEO, molecular imaging and computed tomography (CT), GE Healthcare. “If we can give clinicians a more accurate, reliable and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working after as few as one to two cycles, saving patients unnecessary procedures and a significant amount of money. Q.Clear gives clinicians the ability to help make that determination.” 
 
Clinicians will not only benefit from the ability to detect the smallest lesions, but also the ability to determine earlier whether the metabolic activity is being mitigated under current treatment. Q.Clear aims to provide better quantitation accuracy for personalized medicine. Coupled with GE Healthcare’s Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear will enable clinicians to assess treatment response more accurately than ever before. 
 
Q.Clear is U.S. Food and Drug Administration (FDA) 510(k)-pending and is not yet CE marked. Q.Clear is not available for sale in all regions.
 
For more information: www.gehealthcare.com, www.rsna.org

Related Content

A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve